[1]
|
B. C. Joshi, R. P. Sharma and A. Khare, “Ailanthus Quassinoids and Their Biological Activity,” Natural Product Communications, Vol. 2, No. 8, 2007, pp. 869-880.
|
[2]
|
Z. Guo, S. Vangapandu, R. W. Sindelar, L. A. Walker and R. D. Sindelar, “Biologically Active Quassinoids and Their Chemistry: Potential Leads for Drug Design,” Current Medicinal Chemistry, Vol. 12, No. 2, 2005, pp. 173-190. http://dx.doi.org/10.2174/0929867053363351
|
[3]
|
S. C. Bhatnagar, A. J. Caruso and J. Polonky, “Biologically-Active Quassinoids-Synthetic Methodology for the Conversion of Chaparrin into Glaucarbolone Esters and Quassinoid Analogs,” Tetrahedron, Vol. 43, No. 15, 1987, pp. 3471-3480. http://dx.doi.org/10.1016/S0040-4020(01)81638-0
|
[4]
|
J. Polonsky, “Quassinoid Bitter Principles. II,” Progress in the Chemistry of Organic Natural Products, Vol. 47, 1985, pp. 221-264.
|
[5]
|
R. M. Ekong, G. C. Kirby, G. Patel, J. David Phillipson and D. C. Warhurst, “Comparision of the in Vitro Activities of Quassinoids with Activity against PlasmodiumFalciparum, Anisomycine and Some Other Inhibitors of Eukaryotic Protein-Synthesis,” Biochemical Pharmacology, Vol. 40, No. 2, 1990, pp. 297-301. http://dx.doi.org/10.1016/0006-2952(90)90691-D
|
[6]
|
I. Muhammad and V. Samoylenko, “Antimalarial Quassinoids: Past, Present and Future,” Expert Opinion on Drug Discovery, Vol. 2, 2007, pp. 1065-1084. http://dx.doi.org/10.1517/17460441.2.8.1065
|
[7]
|
H.-S. Kim, Y. Shibata, N. Ko, N. Ikemoto, Y. Ishizuka, et al., “Potent in Vivo Antimalarial Activity of 3,15-di-OAcetylbruceolide against Plasmodium Berghei Infection in Mice,” Parasitology International, Vol. 48, 2000, pp. 271-274. http://dx.doi.org/10.1016/S1383-5769(99)00023-9
|
[8]
|
N. Murakami, M. Sugimoto, M. Kawanishi, S. Tamura, H. S. Kim, et al., “New Semisynthetic Quassinoids with in Vivo Antimalarial Activity,” Journal of Medical Chemistry, Vol. 46, No. 4, 2003, pp. 638-641. http://dx.doi.org/10.1021/jm0201971
|
[9]
|
G. C. Kirby, M. J. O’Neill, J. D. Phillipson and D. C. Warhurst, “In Vitro Studies on the Mode of Action of Quassinoids with Activity Chloroquine-Resistant Plasmodium Falciparum,” Biochemical Pharmacology, Vol. 38, No. 24, 1989, pp. 4367-4374. http://dx.doi.org/10.1016/0006-2952(89)90644-8
|
[10]
|
J. D. Chulay, J. D. Haynes and C. L. Diggs, “Plasmodium-Falciparum—Assessment of in Vitro Growth by [H-3]-Labeled Hypoxanthine Incorporation,” Experimental Parasitology, Vol. 55, No. 1, 1983, pp. 138-146. http://dx.doi.org/10.1016/0014-4894(83)90007-3
|
[11]
|
W. K. Milhous, N. F. Weatherly, J. H. Bowdre and R. E. Desjardins, “In Vitro Activities of and Mechanisms of Resistance to Antifol Antimalarial Drugs,” Antimicrobial Agents Chemotherapy, Vol. 27, No. 4, 1985, pp. 525-530. http://dx.doi.org/10.1128/AAC.27.4.525
|
[12]
|
M. Ogura, G. A. Cordell, D. Kinghorn and N. R. Farnsworth, “Potential Anti-Cancer Agents 6. Constituents of Ailanthus-Excelsa (Simaroubaceae),” Lloydia, Vol. 40, 1977, pp. 579-584.
|
[13]
|
D. J. Morré, P. A. Grieco and D. M. Morré, “Mode of Action of the Anticancer Quassinoids—Inhibition of the Plasma Membrane NADH Oxidase,” Life Sciences, Vol. 63, 1998, pp. 595-604. http://dx.doi.org/10.1016/S0024-3205(98)00310-5
|